Drug Approval | January 21, 2022
Bristol Myers Squibb receives approval for Abecma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Subscribe To Our Newsletter & Stay Updated
